Kymera Therapeutics (KYMR) Change in Accured Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Change in Accured Expenses data on file, last reported at -$7.2 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 38.33% year-over-year to -$7.2 million in Q1 2026; TTM through Mar 2026 was $11.9 million, a 50.53% increase from a year earlier, with the FY2025 full-year figure at $7.4 million, up 76.72% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$7.2 million, down from $13.7 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for KYMR reached as high as $13.7 million in Q4 2025 and fell as low as -$15.4 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $709235.3 across 5 years, with a median of $2.7 million in 2024.
• Across the five-year window, Change in Accured Expenses sank 1069.36% in 2022 and jumped 578.32% in 2023, its largest moves.
• Year by year, Change in Accured Expenses stood at $2.8 million in 2022, then surged by 139.02% to $6.8 million in 2023, then jumped by 32.81% to $9.0 million in 2024, then jumped by 51.43% to $13.7 million in 2025, then sank by 152.77% to -$7.2 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$7.2 million in Q1 2026, $13.7 million in Q4 2025, and $664000.0 in Q3 2025.